Pharma Licensing 2025 and Beyond: Rethinking Strategic Partnerships for Long-Term Value
Introduction: Licensing as a Growth Engine in Pharma The global pharmaceutical and biotech companies are entering an era of collaboration, agility, and strategic alliances. As the R&D cost rises and regulatory timelines stretch, licensing deals have become essential levers for pharma companies to drive innovation and market expansion. Recent data indicate that 68% of blockbuster drugs are now sourced from licensing agreements instead of being developed in-house. In 2025, the focus is shifting from transactional licensing to value-based partnerships. Pharmaceutical leaders are faced with a decision: should they acquire promising compounds from biotech companies or license out their own assets to enhance profits? As this choice will influence the future direction of their companies for years ahead. Understanding In and Out Licensing In-licensing allows companies to acquire external innovations, be it a molecule, technology, or platform, to strengthen their product pipeline wi...